We are live on ! Find out more
LCTX icon

Lineage Cell Therapeutics
LCTX

116 hedge funds and large institutions have $138M invested in Lineage Cell Therapeutics in 2024 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 29 increasing their positions, 32 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more capital invested

Capital invested by funds: $83M → $138M (+$55.2M)

25% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 12

6.02% more ownership

Funds ownership: 43.54% → 49.56% (+6%)

1% more funds holding

Funds holding: 115 → 116 (+1)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

9% less repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 32

Holders
116
Holders Change
+1
Holders Change %
+0.87%
% of All Funds
1.67%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
15
Increased
29
Reduced
32
Closed
12
Calls
$247K
Puts
–
Net Calls
+$247K
Net Calls Change
+$233K

Top Buyers

1
BC
Broadwood Capital
New York
+$7.63M
2
LGM
Logos Global Management
California
+$7.09M
3
DCM
DAFNA Capital Management
California
+$1.55M
4
Bank of America
Bank of America
North Carolina
+$1.46M
5
RA
Raffles Associates
New York
+$1.22M

Top Sellers

1
Morgan Stanley
Morgan Stanley
New York
-$563K
2
LCM
Laurion Capital Management
New York
-$473K
3
Citadel Advisors
Citadel Advisors
Florida
-$415K
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$194K
5
BCM
Bridgeway Capital Management
Texas
-$113K
Name Holding Trade Value Shares
Change 		Change in
Stake
MLICM
101
Metropolitan Life Insurance Company (MetLife)
New York
$2.47K +$1.89K +1,666 New
Carson Wealth (CWM LLC)
102
Carson Wealth (CWM LLC)
Nebraska
$2K +$1.72K +1,513 New
CA
103
Crewe Advisors
Utah
$1.5K +$1.15K +1,016 New
TRCT
104
Tower Research Capital (TRC)
New York
$1.44K -$8.32K -7,335 -88%
BL
105
BFSG LLC
California
$526 +$402 +355 New
AWM
106
Avior Wealth Management
Nebraska
$475 +$24 +21 +7%
PCMC
107
Planning Capital Management Corporation
Pennsylvania
$148 – – –
First Manhattan
108
First Manhattan
New York
$139 – – –
LC
109
Lindbrook Capital
California
$43 -$1.96K -1,725 -98%
CTC
110
Central Trust Company
Missouri
$43 – – –
National Bank of Canada
111
National Bank of Canada
Quebec, Canada
$16 – – –
NFSG
112
Newbridge Financial Services Group
Florida
$7 – – –
DJSG
113
D.J. St. Germain
Massachusetts
$3 – – –
PMFA
114
Plante Moran Financial Advisors
Michigan
$3 – – –
LCM
115
Laurion Capital Management
New York
– -$473K -433,748 Closed
State Board of Administration of Florida Retirement System
116
State Board of Administration of Florida Retirement System
Florida
– -$40.3K -36,970 Closed
HF
117
HRT Financial
New York
– -$39K -35,923 Closed
SG Americas Securities
118
SG Americas Securities
New York
– -$34K -30,889 Closed
CAN
119
Cetera Advisor Networks
California
– -$33.4K -30,628 Closed
XT
120
XTX Topco
Cayman Islands
– -$29.5K -27,037 Closed
AWM
121
AE Wealth Management
Kansas
– -$17.1K -15,543 Closed
TSS
122
Two Sigma Securities
New York
– -$13.8K -12,704 Closed
Fisher Asset Management
123
Fisher Asset Management
Washington
– -$10.9K -10,000 Closed
PNC Financial Services Group
124
PNC Financial Services Group
Pennsylvania
– -$196 -180 Closed
Northwestern Mutual Wealth Management
125
Northwestern Mutual Wealth Management
Wisconsin
– -$22 -20 Closed
2 3 4
5
6

LCTX Hedge Fund Activity: Q1 2024 in Review

116 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q1 2024, worth a combined $138M — up 67% from $83M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new LCTX positions and 12 closed out — a net gain of 3 holders — while 29 added to existing stakes and 32 trimmed.

The largest buyer was Broadwood Capital, adding an estimated $7.63M. The largest seller was Morgan Stanley, cutting an estimated $563K.

  • 116 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q1 2024, up from 115 in Q4 2023.
  • Funds reported $138M of Lineage Cell Therapeutics stock for Q1 2024, up 67% quarter-over-quarter.
  • 15 funds opened new Lineage Cell Therapeutics positions in Q1 2024 and 12 closed out, a net change of +3 holders.
  • The largest Lineage Cell Therapeutics buyer in Q1 2024 was Broadwood Capital, an estimated $7.63M added.
  • The largest Lineage Cell Therapeutics seller in Q1 2024 was Morgan Stanley, an estimated $563K sold.

Based on aggregated 13F filings for Q1 2024.